

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/305,738	05/06/1999	KLAUS MOSBACH	003300-357	2570
75	90 01/20/2004		EXAMI	NER
MORGAN & 345 PARK AVI	FINNEGAN LLP		CEPERLEY, MARY	
NEW YORK, 1			ART UNIT	PAPER NUMBER
·		•	1641	
		,	DATE MAILED: 01/20/2004	
				25

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/305,738	MULLER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Mary (Molly) E. Ceperley	1641				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the o	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed  rs will be considered timely.  the mailing date of this communication.  D (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on 05 No	ovember 2003.	•				
2a)⊠ This action is <b>FINAL</b> . 2b)□ This	action is non-final.					
/ <del></del>	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 27-38 is/are pending in the application	1.	•				
4a) Of the above claim(s) is/are withdrav	vn from consideration.					
5) Claim(s) is/are allowed.						
	6) Claim(s) 27-38 is/are rejected.					
7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	r election requirement					
Application Papers	dicollori requirement.					
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) acce		Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is ob	jected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. §§ 119 and 120						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:  1. ☐ Certified copies of the priority documents	s have been received.					
2. Certified copies of the priority documents	s have been received in Applicati					
<ol> <li>Copies of the certified copies of the prior application from the International Bureau</li> </ol>		ed in this National Stage				
* See the attached detailed Office action for a list		ed.				
13) Acknowledgment is made of a claim for domestic						
since a specific reference was included in the firs 37 CFR 1.78.	st sentence of the specification of	rin an Application Data Sheet.				
a) The translation of the foreign language pro	visional application has been rec	eived.				
14) Acknowledgment is made of a claim for domestic reference was included in the first sentence of the						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)		(PTO-413) Paper No(s)				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	6) 🔲 Other: .					

Art Unit: 1641

1) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

- 2) Claims 34-38 are again rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for the reason set forth in paragraph 8) of the May 05, 2003 Office action. Applicants' arguments filed November 05, 2003 have been fully considered but they are not persuasive. Applicants have apparently misunderstood the rejection of record which is based on the fact that the antibodies of the method of use claims 34 and 35 must, of necessity, have specificity for the drug being assayed. However, the antibodies of claim 27 (from which these claims depend) do not require any particular specificity. This rejection could be overcome by inserting in claim 34, at the end of line 3), the words --wherein the binding sites of the antibodies have specificity for the drug molecule--.
- *3)* Claims 27-38 are again rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over the corresponding claims of U.S. Patent No. 5,959,050 for the reason set forth in paragraph *9)* of the November 05, 2003 Office action. Applicants again offer to file a terminal disclaimer upon the indication of allowable subject matter in this application.
- *4)* Claims 27-38 are again rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Mosbach (U.S. Patent No. 5,110,833) for the reasons set forth in paragraph *10)* of the May 05, 2003 Office action.

Applicants' arguments and the Sigal declaration filed November 05, 2003 have been fully considered but they are not persuasive. Contrary to applicants' characterization of the Mosbach patent, the enabling written disclosure in this reference of molecular imprint polymeric "particles of less than 25 microns" (col. 5, lines 38-40) is considered to specifically describe and therefore anticipate the claimed molecular imprint polymeric particles which have "a particle size of less than about five microns". The

Application/Control Number: 09/305,738

Art Unit: 1641

particles of the Mosbach patent have utility as column chromatography reagents (see col. 5, lines 41-47) and <u>as immunoassay reagents</u> (col. 3, lines 23-28), <u>the same utility recited in instant claim 34</u>. Mosbach further states that "if the imprinted polymers are of a lower molecular weight, these can be applied in a homogenous immunoassay" (col. 3, lines 26-28).

The Mosbach patent by itself anticipates the products of the instant claims, with no consideration of the O'Shannessy references cited by applicants being required to further evaluate the Mosbach patent. Indeed, the O'Shannessy references do not significantly add to the Mosbach disclosure. However, the following comments are made in regard to the characterization of the O'Shannessy references made in the Sigal declaration. The Sigal declaration indicates that the "fines, i.e., the particles that are substantially smaller than 25 microns" are removed from the packing material of the O'Shannessy references thus indicating that these particles have no utility. However, this is not what is specifically stated by the references. O'Shannessy (II) merely makes the following statement:

"Particles which passed through a 25-micron sieve constituted a fraction of <25 microns. In all cases, dust was removed by flotation in acetonitrile, and the particles were finally dried under vacuum."

There is no statement in the reference as to what particle size constitutes "dust". The next section of O'Shannessy (II) then describes the use of particles of <25 microns as packing for high performance liquid chromatography columns:

"Particles <25 microns were slurried by sonication in water-acetonitrile-acetic acid...and packed using the same solvent...".

{The 45-63 micron particles were "dry-packed" rather than "slurried".}

Contrary to the statement made in paragraph 15. of the Sigal declaration, clearly the <25 micron particles of O'Shannessy (II) have a utility. O'Shannessy (I) contains essentially the same disclosure as O'Shannessy (II) (see the last two paragraphs of page 145).

*5)* **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 09/305,738

MONTHS from the mailing date of this final action.

Art Unit: 1641

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX

6) Since the prosecution in this application has proceeded through two final rejections which involved the same issue for appeal, applicants are encouraged to file a Notice of Appeal to further advance the prosecution of this application.

7) Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary (Molly) E. Ceperley whose telephone number is (703) 308-4239. After January 27, 2004, the examiner can be reached at (571) 272-0813. The examiner can normally be reached from 8 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le, can be reached on (703) 305-3399. The central fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

January 13, 2004

Mary (Molly) E. Ceperley

Page 4

Primary Examiner

Art Unit 1641